Aktie A3C15M OCUMETICS TECHNOLOGY CORP.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Ocumetics Technology Corp.

Aktien

A3C15M

CA67577H1047

OTC

Markt geschlossen - Toronto S.E.
Andere Börsenplätze
 17:11:51 15.05.2024 		% 5 Tage % 1. Jan.
0,31 CAD +6,90 % Intraday Chart für Ocumetics Technology Corp. +1,64 % -8,82 %
11.04. Ocumetics Technology Corp. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
2023 Ocumetics Technology Corp. gibt den erfolgreichen Abschluss einer Tierstudie zur Vorbereitung der ersten Studie am Menschen bekannt, die voraussichtlich im ersten Quartal 2024 in der Dominikanischen Republik beginnen wird CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures
Ocumetics Technology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Ocumetics Technology Corp (OTC) To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar (Feb 29, 2024)
Ocumetics Announces Completion of Unit Private Placement
Ocumetics Technology Corp. announced that it has received CAD 0.4166 million in funding
Ocumetics Announces Extension of Private Placement
Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study
Ocumetics Technology Corp. Announces Successful Completion of Animal Study in Preparation for Its First-In-Human Study, Anticipated to Commence in First Quarter of 2024 in the Dominican Republic
Ocumetics Announces Successful Completion of Animal Study Q1 2024 First in Human Study Planned
Ocumetics Technology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Ocumetics Announces Private Placement
Ocumetics Technology Corp. announced that it expects to receive CAD 1 million in funding
Ocumetics Continues to Meet Significant Development Milestones Lens Design Optimized for Upcoming First in Human Study
Ocumetics Continues to Meet Significant Development Milestones; Lens Design Optimized for Upcoming First in Human Study
Ocumetics Welcomes Dr. Doyle Stulting and Dr. Bart McRoberts to Board of Directors
Ocumetics Technology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Ocumetics Technology Corp. announced that it has received CAD 1 million in funding
Ocumetics Announces Completion of First Tranche of Unit Private Placement
Ocumetics Announces Private Placement
Ocumetics Technology Corp. announced that it expects to receive CAD 1 million in funding
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3C15M Aktie
  4. Nachrichten Ocumetics Technology Corp.
  5. Andere Sprachen